Actinium Pharmaceuticals Ownership
| ATNM Stock | USD 1.41 0.03 2.08% |
Shares in Circulation | First Issued 2006-09-30 | Previous Quarter 30.1 M | Current Value 31.1 M | Avarage Shares Outstanding 6.8 M | Quarterly Volatility 9.9 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Actinium |
Actinium Stock Ownership Analysis
About 30.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 1.15. Some equities with similar Price to Book (P/B) outperform the market in the long run. Actinium Pharmaceuticals recorded a loss per share of 1.39. The entity last dividend was issued on the 11th of August 2020. The firm had 1:30 split on the 11th of August 2020. Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant or a type of cellular therapy, and for other adoptive cell therapies. The company was incorporated in 2000 and is based in New York, New York. Actinium Pharmaceuticals operates under Biotechnology classification in the United States and is traded on AMEX Exchange. It employs 32 people. For more info on Actinium Pharmaceuticals please contact MS MBA at 646 677 3870 or go to https://www.actiniumpharma.com.Besides selling stocks to institutional investors, Actinium Pharmaceuticals also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Actinium Pharmaceuticals' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Actinium Pharmaceuticals' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Actinium Pharmaceuticals Quarterly Liabilities And Stockholders Equity |
|
Only 1.78% of Actinium Pharmaceuticals are currently held by insiders. Unlike Actinium Pharmaceuticals' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Actinium Pharmaceuticals' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Actinium Pharmaceuticals' insider trades
Actinium Pharmaceuticals Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Actinium Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Actinium Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Actinium Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Almenoff June Sherie over a month ago Insider Trading | ||
Nicholson, C. David over six months ago Acquisition by Nicholson, C. David of 70311 shares of Actinium Pharmaceuticals at 5.0 subject to Rule 16b-3 | ||
Mark Berger over six months ago Acquisition by Mark Berger of 400000 shares of Actinium Pharmaceuticals at 0.232 subject to Rule 16b-3 | ||
C Nicholson over six months ago Acquisition by C Nicholson of 70311 shares of Actinium Pharmaceuticals subject to Rule 16b-3 |
Actinium Pharmaceuticals Outstanding Bonds
Actinium Pharmaceuticals issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Actinium Pharmaceuticals uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Actinium bonds can be classified according to their maturity, which is the date when Actinium Pharmaceuticals has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| ACTIVISION BLIZZARD INC Corp BondUS00507VAQ23 | View | |
| US00507VAP40 Corp BondUS00507VAP40 | View | |
| ACTIVISION BLIZZARD INC Corp BondUS00507VAM19 | View | |
| ACTIVISION BLIZZARD INC Corp BondUS00507VAK52 | View | |
| ACTAVIS FDG SCS Corp BondUS00507UAS06 | View | |
| BNP Paribas FRN Corp BondUSF1R15XK367 | View |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Trending Equities to better understand how to build diversified portfolios, which includes a position in Actinium Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. To learn how to invest in Actinium Stock, please use our How to Invest in Actinium Pharmaceuticals guide.You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Actinium Pharmaceuticals. If investors know Actinium will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Actinium Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.39) | Revenue Per Share 0.003 | Quarterly Revenue Growth (1.00) | Return On Assets (0.31) | Return On Equity (0.88) |
The market value of Actinium Pharmaceuticals is measured differently than its book value, which is the value of Actinium that is recorded on the company's balance sheet. Investors also form their own opinion of Actinium Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Actinium Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Actinium Pharmaceuticals' market value can be influenced by many factors that don't directly affect Actinium Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Actinium Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Actinium Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Actinium Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.